Good news from Europe about new ovarian cancer drug:
Dr. Andrés Cervantes: ICON7 Results May Change Practice in Ovarian Cancer
OncologySTAT Editorial Team. 2010 Oct 25, Interview by L Scott Zoeller
Andrés Cervantes, MD, PhD, is Chair of the Educational Program for the 2010 Congress of the European Society of Medical Oncology (ESMO).
OncologySTAT: Dr. Cervantes, what were the most important studies in ovarian cancer that were presented at this year’s ESMO Congress?
Dr. Andres Cervantes: For me, the most important study was the ICON7 trial, which was presented during the presidential session of the ESMO Congress…
No new first-line drug has been introduced that has been able to modify the natural history of ovarian cancer since the approval of paclitaxel in 1996. In light of this, I consider these trials to be very important.
Read the entire interview by going to: 2010 Congress of the European Society of Medical Oncology (ESMO) as reported on OncologySTAT.com.
Feel good and keep smiling! Pat & Pattie